Article | June 18, 2020

6 Misconceptions About Automating Cell Therapy Manufacturing

Source: Cytiva

By Per Hammer, ‎Senior Global Product Manager, Cytiva and Alex Nancekievill, Chief Business Officer, Asymptote, Cytiva

Cytiva Chronicle eqt and interface

Controlling quality and variability in drug manufacturing is essential to the safety and efficacy of pharmaceutical products. In biomanufacturing, increased adoption of automated systems is helping to facilitate these tasks while standardizing production. By using automation to minimize human interaction and time and resource requirements, you can increase your product’s speed to market and mitigate many of the risks and costs associated with commercialization.

These innovative solutions improve manufacturing efficiency and support rapidly growing industry sectors, such as cell therapy.  Cell therapies have burst onto the market with great promise to improve patient treatment options and alter clinical care. With the cell therapy market expected to reach over $8.8 billion by 20271, digitizing operations while keeping pace with this emerging space can prove challenging. To safely meet increasing demand, we need to reexamine how best to apply automated solutions.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: